Introduction
============

Smoke inhalation injury, a common complication in patients with thermal injuries, particularly those with flame burns, is an important cause of increased mortality in patients with burns ([@b1-mmr-22-04-3405]--[@b3-mmr-22-04-3405]). According to the current view, thermal injury directly induces respiratory tract damage and the particles and chemicals contained in smoke strongly exacerbate the progression of inhalation injury ([@b4-mmr-22-04-3405]). When various particles and chemical components of smoke, such as dust particles and CO or SO~2~ enter the respiratory tract, these components induce the infiltration of massive numbers of inflammatory cells and the subsequent release of inflammatory mediators into the respiratory tract, stimulating a cascade of stress reactions ([@b5-mmr-22-04-3405],[@b6-mmr-22-04-3405]). The available evidence consistently indicates that the particulate matter in smoke induces direct thermal damage and triggers cytokine production by alveolar macrophages, resulting in a neutrophil-mediated inflammatory response and activation of the NF-κB signal pathway, which contributes to lung injury ([@b7-mmr-22-04-3405]). In addition, previous studies have demonstrated that inducible nitric oxide synthase (iNOS) serves a role in smoke inhalation injury by promoting the apoptosis of alveolar epithelial cells via various signal transduction pathways ([@b8-mmr-22-04-3405]--[@b10-mmr-22-04-3405]). Numerous components of smoke are strong oxidants that can disrupt the redox balance in the body. In addition, the excessive accumulation of inflammatory cells in the lungs leads to the production of excessive reactive oxygen species (ROS), further aggravating the tissue damage caused by oxidative stress ([@b11-mmr-22-04-3405]). The activation of neutrophils and the enhancement of arachidonic acid metabolism following inhalation injury leads to an increase in the production of oxygen free radicals and subsequently causes an increase in the consumption of antioxidant substances ([@b12-mmr-22-04-3405]). Polyunsaturated fatty acids subsequently undergo overoxidation, causing cell damage and accelerating apoptosis, resulting in a decrease in superoxide dismutase (SOD) activity and an increase in malondialdehyde (MDA) content following smoke inhalation injury ([@b13-mmr-22-04-3405]).

Simvastatin, a widely used cholesterol-lowering drug, can substantially reduce the incidence of cardiovascular events in patients with hyperlipidemia ([@b14-mmr-22-04-3405],[@b15-mmr-22-04-3405]). Based on clinical analyses, simvastatin also exerts anti-inflammatory, antioxidant and immunomodulatory effects independent of its lipid-lowering effect ([@b16-mmr-22-04-3405]--[@b18-mmr-22-04-3405]). Some clinical studies have reported that patients with inhalation injury who took statins long-term usually recovered faster ([@b19-mmr-22-04-3405]). The purpose of the present study was to investigate the potential of statins in the treatment of patients with inhalation injury, resolve the underlying mechanisms by which they inhibit the progression of the disease and to evaluate the protective effect exerted by simvastatin against smoke inhalation injury in rats.

Materials and methods
=====================

### Ethics

The present study was approved by the Animal Care and Use Committee of Zhengzhou University (Henan, China) and conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals ([@b20-mmr-22-04-3405]).

A total of 75 male Sprague-Dawley (SD) rats (aged 6--8 weeks, weighing 220--250 g) were provided by the Laboratory Animal Center of Henan Province \[animal certification: SCXK (Yu) 2015-0004\]. The rats were housed under standard conditions, at a temperature of 20--22°C and 40--60% humidity, with a 12-h light/dark cycle and free access to water and food. The rats were acclimated for 1 week before the experiments were performed. The rats were randomly divided into five groups: A control group (uninjured and untreated, n=15), a saline group (treated with saline following smoke exposure, n=15), a low-dose group (treated with 25 mg/kg simvastatin following smoke exposure, n=15), a middle-dose group (treated with 50 mg/kg simvastatin following smoke exposure, n=15) and a high-dose group (treated with 100 mg/kg simvastatin following smoke exposure, n=15). Within the first 30 min following smoke exposure, rats in the low-, middle- and high-dose groups were administered intragastric simvastatin based on their body weight at 12-h intervals and rats in the saline group were administered an equal volume of normal saline.

### Generation of an animal model of smoke inhalation injury

A total of 15 rats were randomly assigned to the control group. The remaining 60 rats were exposed to smoke, which caused smoke inhalation lung injury. The establishment of an animal model of smoke inhalation injury was based on previous experiments and relevant literature ([@b21-mmr-22-04-3405],[@b22-mmr-22-04-3405]). A temperature monitor was installed inside a special glass container with a length, width and height of 50, 35 and 45 cm, respectively, to detect the temperature. Then, 100 g of dry pine chips and 30 ml of kerosene were thoroughly mixed in a pot equipped with a heating device at the bottom and the heating device was switched on 5 min before the experiment. The smoke was wafted from the pot to the glass container using an air blower. After the glass container was loaded with smoke, six rats were arranged in a 30×20×15 cm wire cage and placed into the container. Following a 2-min exposure, the rats were removed from the container and maintained in a normal environment for 5 min. The above procedure was repeated three times, resulting in a cumulative smoke inhalation duration of 6 min. Within the first 30 min following induction of smoke inhalation injury, the low-, middle- and high-dose groups were administered 25, 50 and 100 mg/kg intragastric simvastatin, respectively, according to their weight, every 12 h ([@b23-mmr-22-04-3405]), while the saline group was administered an equal volume of normal saline. At 24, 48 and 72 h following injury, a 10% solution of chloral hydrate was administered for anesthesia via intraperitoneal injection at 300 mg/kg according to their weight. None of the rats exhibited signs of peritonitis, pain or discomfort following administration of chloral hydrate. Blood samples were collected through puncture of the left ventricle, allowed to clot for 60 min and centrifuged at 3,000 × g/min at 4°C for 10 min. At that time point, the weight of each rat was reduced by 10--20 g compared with their previous weights; the maximum percentage of weight loss that was observed in the rats from start to endpoint was 7.3%. Rats were euthanized by exsanguination under anesthesia and the volume of blood collected by exsanguination was 12--17 ml. The lack of a heartbeat, respiratory arrest, absent nerve reflex and muscle relaxation were the parameters used to confirm death before further experiments. The left lungs from the rats were removed for pathological examination and scoring. The mRNA levels of iNOS and caspase-3 in the upper lobes of the right lungs were measured by reverse transcription-quantitative (RT-q) PCR and the protein levels of iNOS and caspase-3 in the middle lobes of the right lungs were measured by western blotting. The activity of SOD and the content of MDA in serum samples and lung tissues obtained from the lower lobes of the right lungs were measured.

### Pathological examination and scoring

Lung tissues were fixed in 10% formalin at room temperature for 24 h, dehydrated through an ascending series of ethanol solutions (70, 80, 95 and 100% alcohol), embedded in paraffin, sectioned to 5-µm thickness and stained with hematoxylin at room temperature for 5 min and followed by eosin at room temperature for 2 min. Then, two experienced pathologists evaluated the tissue morphology under a light microscope (magnification, ×200) in a blinded manner. The severity of the observed lung injuries was scored according to the following criteria: Edema, neutrophil infiltration, hemorrhage and hyaline membrane formation. The severity of lung injury was scored from 0 to 4 as follows: 0, no injury; 1, mild injury; 2, moderate injury; 3, severe injury; and 4, most severe lung injury. Together, five randomly selected sections from each pathological specimen were observed and scored and these scores were added to obtain the lung histopathological score.

### Immunohistochemistry

The immunohistochemical analysis of iNOS and caspase-3 expression in lung tissues was performed in a two-step manner. Sections were deparaffnized at 60°C for 1 h, washed in xylene twice for 10 min and rehydrated in a descending alcohol series. Antigen retrieval was performed for 12 min in a microwave and the tissues were then incubated with primary antibody (iNOS, 1:50; cat. no. ab3523 Abcam and caspase-3, 1:50; cat. no. ab4051 Abcam) at room temperature for 16 h, followed by incubation with horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G (IgG) secondary antibody for 1 h (1:2,000, cat. no. TA130024 OriGene Technologies, Inc.) at room temperature. The tissues were then stained with diaminobenzidine at room temperature for 5 min. The control sections were subjected to the same procedure but without primary antibody incubation. The expression levels of iNOS and caspase-3 in lung tissues were evaluated by two experienced pathologists under a light microscope (magnification, ×400). A cell with a brown cytoplasm or a brown nucleus was considered immunoreactive. All immunoreactive cells in at least five sections from each specimen were counted and the percentage of positive cells was determined, expression levels were quantified using Image-Pro Plus 6.0 (Media Cybernetics, Inc.).

### RT-qPCR

The mRNA expression levels of iNOS and caspase-3 were measured using RT-qPCR. Total RNA was extracted from the upper lobe of the right lung (10--15 g) from each rat using TRIzol^®^ reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. The concentration of RNA was determined using a nanodrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Inc.). RNA (2 µg) was reverse transcribed into cDNA for 5 min at 70°C and 5 min at 4°C using a First-strand cDNA Synthesis kit (Promega Corporation), according to the manufacturer\'s protocol. qPCR was performed using a qPCR Master mix (New England Biolabs, Inc.) and 96-well optical reaction plates and the CFX96 Real-Time PCR detection system (Bio-Rad Laboratories, Inc.). The following PCR conditions were used: Predenaturation at 95°C for 60 sec followed by 40 cycles of denaturation at 95°C for 15 sec and extension at 60°C for 45 sec, according to the manufacturer\'s protocol. All experiments were performed four times. The primers were provided by Sangon Biotech (Shanghai) Co., Ltd. The primer sequences for GAPDH were: Forward: 5′-AACATCCAGAGCTTGACGGTG−3′ and reverse: 5′-TCTTGACCATCCTTGAGAGTGG-3′ and the primer sequences for iNOS were forward: 5′-AACCCAAGGTCTACGTTCAAG−3′ and reverse: 5′-AAAGTGGTAGCCACATCCCG-3′. The primer sequences for caspase-3 were forward: 5′-TGGTTCATCCAGTCGCTTTGT−3′ and reverse: 5′-CAAATTCTGTTGCCACCTTTCG-3′. Relative gene expression levels were calculated using the relative quantification 2^−ΔΔCq^ method and normalized to GAPDH ([@b24-mmr-22-04-3405]).

### Western blotting

The protein expression levels of iNOS and caspase-3 in lung tissues were evaluated using western blotting. The proteins from the middle lobe tissue from the right lung of each rat were extracted using RIPA lysis buffer (Biotechwell) supplemented with phenylmethylsulfonyl fluoride and the supernatant was collected. The protein concentration was measured with a Bicinchoninic Acid Assay kit (Biotechwell: <http://www.biotechwell.com>). Then, 40 µg protein/lane was separated by 12% SDS-PAGE. The separated proteins were subsequently transferred onto PVDF membranes (EMD Millipore) and blocked for 2 h at room temperature with 5% non-fat milk solution. The membranes were incubated with a rabbit anti-iNOS polyclonal antibody (1:200, cat. no. ab3523 Abcam), rabbit anti-caspase-3 polyclonal antibody (1:100, cat. no. ab4051 Abcam), or rabbit anti-β-actin polyclonal antibody (1:500, cat. no. ab6276 Abcam) in tris-buffered saline and Tween 20 (0.1%) TBST overnight at 4°C. The membranes were then incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG secondary antibody (1:2,000, cat. no. TA130024 OriGene Technologies, Inc.) for 1.5 h at room temperature. The resulting bands were detected with an enhanced chemiluminescence detection system, using the Pierce^™^ ECL Western Blotting Substrate (Bio-Rad Laboratories, Inc.). Protein expression was semi-quantified using Image-Pro Plus version 6.0 software (Media Cybernetics, Inc.) with β-actin as the loading control.

### Measurement of SOD activity and MDA content

Using precooled saline as the medium, homogenates of the right lung lower lobes were centrifuged at 3,000 × g/min for 15 min at 4°C and the supernatants were collected. The assays were performed according to the manufacturer\'s instructions. The MDA content in the supernatant and serum was measured using the thiobarbituric acid method (Nanjing Jiancheng Bioengineering Institute). The absorbance values used for the MDA measurements were obtained at 532 nm by microplate reader and converted to nmol/mg protein or nmol/ml. SOD activity in the supernatant and serum was measured using the WST-1 method (Nanjing Jiancheng Bioengineering Institute). The absorbance values used for the measurements of SOD activity in supernatant and serum were obtained at 450 nm by microplate reader and converted to U/mg protein or U/ml.

### Statistical analysis

All data were expressed as the mean ± standard deviation. The data were subjected to statistical analyses using SPSS version 22 software (IBM, Corp). The homogeneity of variance was first determined using Levene\'s test. One way Analysis of variance was used for overall comparisons between groups and Tukey\'s post hoc test when the homogeneity of variance assumption was met or by the Games-Howell test when the homogeneity of variance assumption was not met. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Pathological examination and scores

The inflammatory response was significantly reduced following the administration of simvastatin. Higher pathological scores were obtained in the saline and low-, middle- and high-dose groups compared with the control group (P\<0.05). In addition, the pathological scores of the low-, middle- and high-dose groups were lower compared with the saline group (P\<0.05). Additionally, the scores of the middle- and high-dose groups were lower compared with the low-dose group (P\<0.05). The difference between the middle- and high-dose groups was non-significant (P\>0.05; [Figs. 1](#f1-mmr-22-04-3405){ref-type="fig"}, [2](#f2-mmr-22-04-3405){ref-type="fig"} and [3](#f3-mmr-22-04-3405){ref-type="fig"}; statistical data not shown).

### Immunohistochemistry

Based on immunohistochemical analysis, iNOS ([Figs. 4](#f4-mmr-22-04-3405){ref-type="fig"}, [5](#f5-mmr-22-04-3405){ref-type="fig"} and [6](#f6-mmr-22-04-3405){ref-type="fig"}; statistical data not shown) and caspase-3 ([Figs. 7](#f7-mmr-22-04-3405){ref-type="fig"}, [8](#f8-mmr-22-04-3405){ref-type="fig"} and [9](#f9-mmr-22-04-3405){ref-type="fig"}; statistical data not shown) expression levels were higher in the saline and theablr low-, medium- and high-dose groups compared with the control group (P\<0.05); lower in the low-, middle- and high-dose groups compared with the saline group (P\<0.05); and lower in the middle- and high-dose groups compared with the low-dose group (P\<0.05). The difference between the middle- and high-dose groups was non-significant (P\>0.05).

### RT-qPCR

RT-qPCR revealed that iNOS and caspase-3 mRNA expression levels were lower in the low-, middle- and high-dose groups compared with the saline group (P\<0.01 or 0.05) and lower in the middle- and high-dose groups compared with the low-dose group (P\<0.01 or 0.05). The difference between the middle- and high-dose groups was not significant (P\>0.05; [Figs. 10](#f10-mmr-22-04-3405){ref-type="fig"}, [11](#f11-mmr-22-04-3405){ref-type="fig"} and [12](#f12-mmr-22-04-3405){ref-type="fig"}).

### Western blot analysis

Western blot analysis demonstrated that the protein levels of iNOS and caspase-3 were higher in the saline, low-dose, middle-dose and high-dose groups compared with the control group (P\<0.01 or P\<0.05). Additionally, the protein levels were lower in the low-, middle- and high-dose groups compared with the saline group (P\<0.01 or P\<0.05) and lower in the middle- and high-dose groups compared with the low-dose group (P\<0.01 or P\<0.05). However, no significant difference in the protein levels of iNOS and caspase-3 was observed between the middle- and high-dose groups (P\>0.05; [Figs. 13](#f13-mmr-22-04-3405){ref-type="fig"}, [14](#f14-mmr-22-04-3405){ref-type="fig"} and [15](#f15-mmr-22-04-3405){ref-type="fig"}).

### SOD activity and content of MDA

SOD activity in lung tissues and serum was lower in the saline group and the low-, middle- and high-dose groups compared with the control group (P\<0.05); significantly higher in the low-, medium- and high-dose groups compared with the saline group (P\<0.05); and higher in the middle- and high-dose groups compared with the low-dose group (P\<0.05) at 24, 48 and 72 h. No significant difference in the SOD activity in lung tissues and serum was observed between the middle- and high-dose groups (P\>0.05), with the exception of at 24 and 72 h in lung tissues. MDA content in lung tissues and serum was higher in the saline, low-dose, middle-dose and high-dose groups compared with the control group (P\<0.05). Additionally, the MDA content were lower in the low-, middle- and high-dose groups compared with the saline group (P\<0.05) and lower in the middle- and high-dose groups compared with the low-dose group (P\<0.05). The difference between the middle- and high-dose groups was not significant (P\>0.05) except the MDA content in serum at 48 h ([Tables I](#tI-mmr-22-04-3405){ref-type="table"} and [II](#tII-mmr-22-04-3405){ref-type="table"}).

Discussion
==========

At present, the pathogenesis of inhaled lung injury has yet to be fully elucidated and sufficient evidence from basic research and clinical data is lacking. Previous research on smoke inhalation injury has primarily focused on inflammation and oxidative stress ([@b25-mmr-22-04-3405],[@b26-mmr-22-04-3405]). For example, one study demonstrated that NF-κB, tumor necrosis factor (TNF) α and interleukin (IL) 6 serve key roles in smoke inhalation injury ([@b27-mmr-22-04-3405]). During the process of inhalation injury, intracellular quiescent NF-κB is activated as a result of the phosphorylation and degradation of inhibitor of NF-κB (IκB) and the two of these processes occur when cells are stimulated with various cytokines such as TNF-α and IL-6. Activated NF-κB translocates to the nucleus to regulate the transcription of its target genes, including cytokines, inflammatory mediators, acute phase proteins and inducible effector enzymes ([@b28-mmr-22-04-3405],[@b29-mmr-22-04-3405]). In previous experimental studies, our research group has demonstrated that simvastatin can significantly reduce the mortality of animal models with smoke inhalation lung injury, alleviate the inflammatory response in lung tissue and significantly reduce the content of NF-κB ([@b30-mmr-22-04-3405],[@b31-mmr-22-04-3405]). Treatment with simvastatin inactivates NF-κB by increasing the number of IκB molecules, which is regarded as an inhibitor of NF-κB and decreases the nuclear NF-κB content. The inhibitory effect of statins might be mediated by isoprenoid-induced intracellular signal transduction, which involves several key signaling proteins, including Rho kinase and IκB/NF-κB ([@b32-mmr-22-04-3405]).

NO has become the focus of studies investigating the mechanism underlying the gradual induction of lung tissue damage in smoke inhalation injury ([@b33-mmr-22-04-3405],[@b34-mmr-22-04-3405]). Endogenous NO is a transduction molecule involved in the intracellular signaling pathway and NO also affects arterial dilatation, decreases platelet viscosity and acts as an anti-inflammatory agent ([@b35-mmr-22-04-3405]). According to previous studies, NO regulates apoptosis and inhibits the activities of several caspases ([@b36-mmr-22-04-3405],[@b37-mmr-22-04-3405]). The overproduction of NO mediates mitochondrial dysfunction and triggers apoptosis and, as more in-depth studies are being performed, the role of NO in the progression of smoke inhalation-induced lung injury is gradually attracting more attention ([@b38-mmr-22-04-3405]).

A previous study demonstrated that NO is produced by three types of NOS: Endothelial NOS, iNOS and neuronal NOS ([@b39-mmr-22-04-3405]). During smoke inhalation injury, large quantities of active iNOS catalyze the decomposition of arginine to produce an excessive amount of NO ([@b40-mmr-22-04-3405]). Simultaneously, excess NO binds to O2^−^ to form a strong oxidant (ONOO^−^) that mediates the production of a large amount of ROS, resulting in destruction of the cytomembrane and DNA, inducing cell lysis and necrosis ([@b41-mmr-22-04-3405]). ONOO^−^ acts mainly through two pathways: i) It affects pulmonary vascular permeability and the diffusion function of lung tissue, ii) it destroys the cytomembrane and DNA and iii) affects the energy metabolism of cells through negative feedback, leading to cell lysis and necrosis ([@b42-mmr-22-04-3405]). One subtype of histone deacetylase, sirtuin 1 (SIRT1) serves an important role in maintaining gene stability, inhibiting apoptosis, inhibiting oxidative stress and exerting anti-inflammatory effects ([@b43-mmr-22-04-3405]). However, excessive production of NO can inhibit SIRT1, thereby inhibiting P53 pathway-dependent apoptosis through a deacetylation pathway and ultimately promoting apoptosis ([@b44-mmr-22-04-3405]).

However, NO also activates protein kinase G (PKG), through the NO/cyclic guanosine monophosphate/PKG pathway ([@b45-mmr-22-04-3405]). Additionally, phosphorylated p38 mitogen-activated protein kinase activates caspase-3 ([@b46-mmr-22-04-3405]). Caspase-3, which serves as an intersection of the endogenous and exogenous apoptotic pathways, is the main protein with apoptotic activity ([@b47-mmr-22-04-3405]). Therefore, its expression levels can directly reflect the occurrence of apoptosis ([@b48-mmr-22-04-3405]). Associated inflammatory mediators and cells regulated by NF-κB can further promote the activation of NF-κB, TNF-α, IL-6 and iNOS, among other factors, indicating that NF-κB serves a key role in smoke inhalation injury ([@b49-mmr-22-04-3405]). Pro-inflammatory cytokines, such as IL-1 and TNF-α, induce the expression of iNOS and consequently the generation of large quantities of NO, resulting in cell degeneration and apoptosis ([@b50-mmr-22-04-3405]).

Toll-like receptor 4 (TLR4), one of the most important proteins involved in cellular signaling, activates the downstream nuclear factor NF-κB when bound to its ligand ([@b51-mmr-22-04-3405]). Combined with the present results, it can be hypothesized that simvastatin decreases the expression of iNOS and caspase-3 by inhibiting the activation of NF-κB, which in turn is mediated by suppressing TLR4 expression on the surfaces of CD14+ monocytes in peripheral blood and attenuating downstream signal pathways. This protects the lungs against cytotoxicity caused by NF-κB and NO overproduction, and decreasing cell damage and apoptosis ([@b52-mmr-22-04-3405]). At the same time, overproduction of NO can block the high levels of Ca^2+^ induced by ROS and inhibit apoptosis through the Bcl-2 signaling pathway ([@b53-mmr-22-04-3405]).

The levels of MDA, a product of the destruction of polyunsaturated fatty acids in the cell membrane, indirectly reflects the grade of oxidative damage. SOD acts as an important antioxidant enzyme by antagonizing and blocking oxygen free radicals to decrease cell damage and thus speeding the repair of free radical-induced damage in cells ([@b54-mmr-22-04-3405],[@b55-mmr-22-04-3405]). High levels of oxygen free radicals exceed the capacity of the antioxidant system during smoke inhalation injury, which causes lipid peroxidation and subsequent destruction of cell membranes ([@b56-mmr-22-04-3405]). Simvastatin decreases the activation of neutrophils and arachidonic acid metabolism following inhalation injury, leading to a decrease in the production of oxygen free radicals and a consequential consumption of antioxidant substances. In turn, this increases SOD production and inhibits oxidative stress in response to smoke inhalation injury, thus reducing cell damage ([@b57-mmr-22-04-3405],[@b58-mmr-22-04-3405]).

In the present study, iNOS and caspase-3 expression levels were significantly increased following smoke inhalation lung injury (P\<0.05), indicating that lung tissue injury was aggravated, whereas iNOS and caspase-3 expression levels in the low-, middle- and high-dose groups were significantly lower compared with the saline group (P\<0.05). As an important antioxidant enzyme *in vivo*, SOD activity was significantly decreased following smoke inhalation lung injury (P\<0.05) and MDA content was significantly increased (P\<0.05), at 24, 48 and 72 h. In addition, simvastatin treatment increased SOD activity and decreased the MDA content, and this effect was dose-dependent within 0--50 mg/kg. Therefore, simvastatin could inhibit the formation of iNOS and inhibit apoptosis and lung tissue damage following smoke inhalation, thus exerting a certain protective effect on lung tissue with smoke inhalation injury. Although the therapeutic effect of simvastatin on inhalation injury has been widely recognized ([@b59-mmr-22-04-3405]), the specific underlying molecular mechanisms and appropriate dosages remain unclear.

In the present study, simvastatin inhibited iNOS and caspase-3 expression and decreased NO synthesis and lung cell apoptosis. In contrast, simvastatin exerted some antioxidant effects and inhibited excessive oxidative stress in rats with smoke inhalation injury, thus exerting a protective effect against smoke inhalation injury.
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![Pathological changes in lung tissue at 24 h. (A) Control group: The alveolar structure of lung tissues from the control group was complete, with uniform alveolar intervals and an alveolar cavity showing no evident inflammatory cell infiltration or edema. Following exposure to smoke, lung tissue edema was accompanied by varying degrees of exudation, alveolar septal edema, hemorrhage and inflammatory cell infiltration. The alveolar cavity contained a large number of inflammatory cells and a large amount of erythrocyte exudation. (B) Saline group, (C) low-dose group, (D) middle-dose group and (E) high-dose group. Scale bars, 200 µm; magnification, ×200; hematoxylin and eosin staining.](MMR-22-04-3405-g00){#f1-mmr-22-04-3405}

![Pathological changes in lung tissue at 48 h. (A) Control group: The alveolar structure of lung tissues from the control group was complete, with uniform alveolar intervals and an alveolar cavity showing no evident inflammatory cell infiltration or edema. Following exposure to smoke, lung tissue edema was accompanied by varying degrees of exudation, alveolar septal edema, hemorrhage and inflammatory cell infiltration. The alveolar cavity contained a large number of inflammatory cells and a large amount of erythrocyte exudation. (B) Saline group, (C) low-dose group, (D) middle-dose group and (E) high-dose group. Scale bars, 200 µm; magnification, ×200; hematoxylin and eosin staining.](MMR-22-04-3405-g01){#f2-mmr-22-04-3405}

![Pathological changes in lung tissue at 72 h. (A) Control group: The alveolar structure of lung tissues from the control group was complete, with uniform alveolar intervals and an alveolar cavity showing no evident inflammatory cell infiltration or edema. Following exposure to smoke, lung tissue edema was accompanied by varying degrees of exudation, alveolar septal edema, hemorrhage and inflammatory cell infiltration. The alveolar cavity contained a large number of inflammatory cells and a large amount of erythrocyte exudation. (B) Saline group, (C) low-dose group, (D) middle-dose group and (E) high-dose group. Scale bars, 200 µm; magnification, ×200; hematoxylin and eosin staining.](MMR-22-04-3405-g02){#f3-mmr-22-04-3405}

![Expression of iNOS in lung tissue at 24 h. iNOS was mainly expressed in bronchial epithelial cells, alveolar epithelial cells and vascular and airway smooth muscle cells. Higher iNOS expression levels were detected in the saline, low-dose, middle-dose and high-dose groups compared with the control group. (A) Control group, (B) saline group, (C) low-dose group, (D) middle-dose group, (E) high-dose group and (F) PBS group. Scale bars, 100 µm; magnification, ×400; DAB staining. iNOS, inducible nitric oxide synthase; DAB, 3,3-diaminobenzidine.](MMR-22-04-3405-g03){#f4-mmr-22-04-3405}

![Expression of iNOS in lung tissue at 48 h. iNOS was mainly expressed in bronchial epithelial cells, alveolar epithelial cells and vascular and airway smooth muscle cells. Higher iNOS expression levels were detected in the saline, low-dose, middle-dose and high-dose groups compared with the control group. (A) Control group, (B) saline group, (C) low-dose group, (D) middle-dose group, (E) high-dose group and (F) PBS group. Scale bars, 100 µm; magnification, ×400; DAB staining. iNOS, inducible nitric oxide synthase; DAB, 3,3-diaminobenzidine.](MMR-22-04-3405-g04){#f5-mmr-22-04-3405}

![Expression of iNOS in lung tissue at 72 h. iNOS was mainly expressed in bronchial epithelial cells, alveolar epithelial cells and vascular and airway smooth muscle cells. Higher iNOS expression levels were detected in the saline, low-dose, middle-dose and high-dose groups compared with the control group. (A) Control group, (B) saline group, (C) low-dose group, (D) middle-dose group, (E) high-dose group and (F) PBS group. Scale bars, 100 µm; magnification, ×400; DAB staining. iNOS, inducible nitric oxide synthase; DAB, 3,3-diaminobenzidine.](MMR-22-04-3405-g05){#f6-mmr-22-04-3405}

![Expression of caspase-3 in lung tissue at 24 h. Caspase-3 was mainly expressed in bronchial epithelial cells, alveolar epithelial cells and vascular and airway smooth muscle cells. The caspase-3 expression levels in the saline, low-, middle- and high-dose groups were higher compared with the normal group. (A) Control group, (B) saline group, (C) low-dose group, (D) middle-dose group, (E) high-dose group and (F) PBS group. Scale bars, 100 µm; magnification, ×400; DAB staining. DAB, 3,3-diaminobenzidine.](MMR-22-04-3405-g06){#f7-mmr-22-04-3405}

![Expression of caspase-3 in lung tissue at 48 h. Caspase-3 was mainly expressed in bronchial epithelial cells, alveolar epithelial cells and vascular and airway smooth muscle cells. The caspase-3 expression levels in the saline, low-, middle- and high-dose groups were higher compared with the normal group. (A) Control group, (B) saline group, (C) low-dose group, (D) middle-dose group, (E) high-dose group and (F) PBS group. Scale bars, 100 µm; magnification, ×400; DAB staining. DAB, 3,3-diaminobenzidine.](MMR-22-04-3405-g07){#f8-mmr-22-04-3405}

![Expression of caspase-3 in lung tissue at 72 h. Caspase-3 was mainly expressed in bronchial epithelial cells, alveolar epithelial cells and vascular and airway smooth muscle cells. The caspase-3 expression levels in the saline, low-, middle- and high-dose groups were higher compared with the normal group. (A) Control group, (B) saline group, (C) low-dose group, (D) middle-dose group, (E) high-dose group and (F) PBS group. Scale bars, 100 µm; magnification, ×400; DAB staining. DAB, 3,3-diaminobenzidine.](MMR-22-04-3405-g08){#f9-mmr-22-04-3405}

![Relative mRNA expression levels of iNOS and caspase-3 at 24 h. The levels of the iNOS and caspase-3 mRNA were lower in the low-, middle- and high-dose groups compared with the saline group. \*P\<0.05, \*\*P\<0.01 vs. saline group; ^\#^P\<0.05, ^\#\#^P\<0.01 vs. low-dose group. iNOS, inducible nitric oxide synthase; S, saline group; L, low-dose group; M, middle-dose group; H, high-dose group.](MMR-22-04-3405-g09){#f10-mmr-22-04-3405}

![Relative mRNA expression levels of iNOS and caspase-3 at 48 h. The levels of the iNOS and caspase-3 mRNA were lower in the low-, middle- and high-dose groups compared with the saline group. \*\*P\<0.01 vs. saline group; ^\#^P\<0.05, ^\#\#^P\<0.01 vs. low-dose group. iNOS, inducible nitric oxide synthase; S, saline group; L, low-dose group; M, middle-dose group; H, high-dose group.](MMR-22-04-3405-g10){#f11-mmr-22-04-3405}

![Relative mRNA expression levels of iNOS and caspase-3 at 72 h. The levels of the iNOS and caspase-3 mRNA were lower in the low-, middle- and high-dose groups compared with the saline group. \*P\<0.05, \*\*P\<0.01 vs. saline group; ^\#^P\<0.05, ^\#\#^P\<0.01 vs. low-dose group. iNOS, inducible nitric oxide synthase; S, saline group; L, low-dose group; M, middle-dose group; H, high-dose group.](MMR-22-04-3405-g11){#f12-mmr-22-04-3405}

![Relative expression of iNOS and caspase-3 in lung tissue at 24 h. The levels of iNOS and caspase-3 proteins in rat lungs were detected and immunoreactive bands were observed at \~131 and 17 kDa, respectively. The levels of the iNOS and caspase-3 proteins were higher in the saline, low-, middle- and high-dose groups compared with the control group. \*\*P\<0.01 vs. control group; ^\#^P\<0.05, ^\#\#^P\<0.01 vs. saline group; ^\$^P\<0.05, ^\$\$^P\<0.01 vs. low-dose group. iNOS, inducible nitric oxide synthase; N, control group S, saline group; L, low-dose group; M, middle-dose group; H, high-dose group.](MMR-22-04-3405-g12){#f13-mmr-22-04-3405}

![Relative expression of iNOS and caspase-3 in lung tissue at 48 h. The levels of iNOS and caspase-3 proteins in rat lungs were detected and immunoreactive bands were observed at \~131 and 17 kDa, respectively. The levels of the iNOS and caspase-3 proteins were higher in the saline, low-, middle- and high-dose groups compared with the control group. \*\*P\<0.01 vs. control group; ^\#\#^P\<0.01 vs. saline group; ^\$\$^P\<0.01 vs. low-dose group. iNOS, inducible nitric oxide synthase; N, control group S, saline group; L, low-dose group; M, middle-dose group; H, high-dose group.](MMR-22-04-3405-g13){#f14-mmr-22-04-3405}

![Relative expression of iNOS and caspase-3 in lung tissue at 72 h. The levels of iNOS and caspase-3 proteins in rat lungs were detected and immunoreactive bands were observed at \~131 and 17 kDa, respectively. The levels of the iNOS and caspase-3 proteins were higher in the saline, low-, middle- and high-dose groups compared with the control group. \*\*P\<0.01 vs. control group; ^\#\#^P\<0.01 vs. saline group; ^\$\$^P\<0.01 vs. low-dose group. iNOS, inducible nitric oxide synthase; N, control group S, saline group; L, low-dose group; M, middle-dose group; H, high-dose group.](MMR-22-04-3405-g14){#f15-mmr-22-04-3405}

###### 

Activity of superoxide dismutase in lung tissue (U/mg prot) and serum (U/ml) at different time points and different doses of simvastatin.

                      24 h                                                                                                         48 h                                                                                                          72 h                                                                                                                                                                                                                                                                                                                                    
  ------------------- ------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------
  Control group       59.92±8.13                                                                                                   250.8±11.27                                                                                                   57.83±6.67                                                                                                   244.25±11.58                                                                                                  60.31±2.29                                                                                                   248.03±3.67
  Saline group        16.32±1.67^[a](#tfn2-mmr-22-04-3405){ref-type="table-fn"}^                                                   161.45±10.51^[a](#tfn2-mmr-22-04-3405){ref-type="table-fn"}^                                                  16.45±1.30^[a](#tfn2-mmr-22-04-3405){ref-type="table-fn"}^                                                   164.95±14.97^[a](#tfn2-mmr-22-04-3405){ref-type="table-fn"}^                                                  19.96±1.53^[a](#tfn2-mmr-22-04-3405){ref-type="table-fn"}^                                                   157.79±4.97^[a](#tfn2-mmr-22-04-3405){ref-type="table-fn"}^
  Low-dose group      23.81±3.53^[a](#tfn2-mmr-22-04-3405){ref-type="table-fn"},[b](#tfn3-mmr-22-04-3405){ref-type="table-fn"}^    183.77±9.22^[a](#tfn2-mmr-22-04-3405){ref-type="table-fn"},[b](#tfn3-mmr-22-04-3405){ref-type="table-fn"}^    28.26±3.09^[a](#tfn2-mmr-22-04-3405){ref-type="table-fn"},[b](#tfn3-mmr-22-04-3405){ref-type="table-fn"}^    189.14±10.01^[a](#tfn2-mmr-22-04-3405){ref-type="table-fn"},[b](#tfn3-mmr-22-04-3405){ref-type="table-fn"}^   27.78±2.03^[a](#tfn2-mmr-22-04-3405){ref-type="table-fn"},[b](#tfn3-mmr-22-04-3405){ref-type="table-fn"}^    197.65±7.57^[a](#tfn2-mmr-22-04-3405){ref-type="table-fn"},[b](#tfn3-mmr-22-04-3405){ref-type="table-fn"}^
  Middle-dose group   39.57±6.34^[a](#tfn2-mmr-22-04-3405){ref-type="table-fn"}--[c](#tfn4-mmr-22-04-3405){ref-type="table-fn"}^   215.03±9.19^[a](#tfn2-mmr-22-04-3405){ref-type="table-fn"}--[c](#tfn4-mmr-22-04-3405){ref-type="table-fn"}^   43.76±5.56^[a](#tfn2-mmr-22-04-3405){ref-type="table-fn"}--[c](#tfn4-mmr-22-04-3405){ref-type="table-fn"}^   220.41±6.05^[a](#tfn2-mmr-22-04-3405){ref-type="table-fn"}--[c](#tfn4-mmr-22-04-3405){ref-type="table-fn"}^   38.73±3.08^[a](#tfn2-mmr-22-04-3405){ref-type="table-fn"}--[c](#tfn4-mmr-22-04-3405){ref-type="table-fn"}^   213.84±6.93^[a](#tfn2-mmr-22-04-3405){ref-type="table-fn"}--[c](#tfn4-mmr-22-04-3405){ref-type="table-fn"}^
  High-dose group     39.77±4.90^[a](#tfn2-mmr-22-04-3405){ref-type="table-fn"}--[c](#tfn4-mmr-22-04-3405){ref-type="table-fn"}^   226.97±7.37^[a](#tfn2-mmr-22-04-3405){ref-type="table-fn"}--[d](#tfn5-mmr-22-04-3405){ref-type="table-fn"}^   43.04±5.10^[a](#tfn2-mmr-22-04-3405){ref-type="table-fn"}--[c](#tfn4-mmr-22-04-3405){ref-type="table-fn"}^   224.99±1.85^[a](#tfn2-mmr-22-04-3405){ref-type="table-fn"}--[c](#tfn4-mmr-22-04-3405){ref-type="table-fn"}^   39.86±4.60^[a](#tfn2-mmr-22-04-3405){ref-type="table-fn"}--[c](#tfn4-mmr-22-04-3405){ref-type="table-fn"}^   227.52±10.05^[a](#tfn2-mmr-22-04-3405){ref-type="table-fn"}--[d](#tfn5-mmr-22-04-3405){ref-type="table-fn"}^

All the values are expressed as the mean ± standard deviation.

P\<0.05 vs. control group

P\<0.05 vs. saline group

P\<0.05 vs. low-dose group

P\<0.05, vs. middle-dose group.

###### 

Malondialdehyde in lung tissue (nmol/mg prot) and serum (nmol/ml) at different time points and different doses of simvastatin.

                24 h                                                                                                        48 h                                                                                                        72 h                                                                                                                                                                                                                                                                                                                                 
  ------------- ----------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------
  Control       4.43±0.65                                                                                                   3.59±0.33                                                                                                   4.28±0.47                                                                                                    3.33±0.27                                                                                                   4.58±0.43                                                                                                   3.88±0.13
  Saline        11.11±2.14^[a](#tfn7-mmr-22-04-3405){ref-type="table-fn"}^                                                  9.68±0.89^[a](#tfn7-mmr-22-04-3405){ref-type="table-fn"}^                                                   10.11±0.60^[a](#tfn7-mmr-22-04-3405){ref-type="table-fn"}^                                                   10.33±0.87^[a](#tfn7-mmr-22-04-3405){ref-type="table-fn"}^                                                  9.95±0.62^[a](#tfn7-mmr-22-04-3405){ref-type="table-fn"}^                                                   10.28±0.38^[a](#tfn7-mmr-22-04-3405){ref-type="table-fn"}^
  Low-dose      8.95±0.65^[a](#tfn7-mmr-22-04-3405){ref-type="table-fn"},[b](#tfn8-mmr-22-04-3405){ref-type="table-fn"}^    7.43±0.86^[a](#tfn7-mmr-22-04-3405){ref-type="table-fn"},[b](#tfn8-mmr-22-04-3405){ref-type="table-fn"}^    8.59±0.57^[a](#tfn7-mmr-22-04-3405){ref-type="table-fn"},[b](#tfn8-mmr-22-04-3405){ref-type="table-fn"}^     7.68±1.11^[a](#tfn7-mmr-22-04-3405){ref-type="table-fn"},[b](#tfn8-mmr-22-04-3405){ref-type="table-fn"}^    8.37±0.20^[a](#tfn7-mmr-22-04-3405){ref-type="table-fn"},[b](#tfn8-mmr-22-04-3405){ref-type="table-fn"}^    8.51±0.71^[a](#tfn7-mmr-22-04-3405){ref-type="table-fn"},[b](#tfn8-mmr-22-04-3405){ref-type="table-fn"}^
  Middle-dose   7.64±0.34^[a](#tfn7-mmr-22-04-3405){ref-type="table-fn"}--[c](#tfn9-mmr-22-04-3405){ref-type="table-fn"}^   5.57±0.68^[a](#tfn7-mmr-22-04-3405){ref-type="table-fn"}--[c](#tfn9-mmr-22-04-3405){ref-type="table-fn"}^   7.22±0.38^[a](#tfn7-mmr-22-04-3405){ref-type="table-fn"}--[c](#tfn9-mmr-22-04-3405){ref-type="table-fn"}^    5.68±0.84^[a](#tfn7-mmr-22-04-3405){ref-type="table-fn"}--[c](#tfn9-mmr-22-04-3405){ref-type="table-fn"}^   6.66±0.59^[a](#tfn7-mmr-22-04-3405){ref-type="table-fn"}--[c](#tfn9-mmr-22-04-3405){ref-type="table-fn"}^   4.92±0.34^[a](#tfn7-mmr-22-04-3405){ref-type="table-fn"}--[c](#tfn9-mmr-22-04-3405){ref-type="table-fn"}^
  High-dose     6.65±0.37^[a](#tfn7-mmr-22-04-3405){ref-type="table-fn"}--[c](#tfn9-mmr-22-04-3405){ref-type="table-fn"}^   5.19±0.37^[a](#tfn7-mmr-22-04-3405){ref-type="table-fn"}--[c](#tfn9-mmr-22-04-3405){ref-type="table-fn"}^   6.08±0.68^[a](#tfn7-mmr-22-04-3405){ref-type="table-fn"}--[d](#tfn10-mmr-22-04-3405){ref-type="table-fn"}^   5.24±0.29^[a](#tfn7-mmr-22-04-3405){ref-type="table-fn"}--[c](#tfn9-mmr-22-04-3405){ref-type="table-fn"}^   6.08±0.66^[a](#tfn7-mmr-22-04-3405){ref-type="table-fn"}--[c](#tfn9-mmr-22-04-3405){ref-type="table-fn"}^   4.99±0.26^[a](#tfn7-mmr-22-04-3405){ref-type="table-fn"}--[c](#tfn9-mmr-22-04-3405){ref-type="table-fn"}^

All the values are expressed as the mean ± standard deviation.

P\<0.05, vs. control group

P\<0.05, vs. saline group

P\<0.05. vs. low-dose group

P\<0.05, vs. middle-dose group.
